Despite all of the efforts in the field of cancer therapy, the heterogeneous properties of tumor cells induce an insufficient therapeutic outcome when treated with conventional monotherapies, necessitating a shift in cancer treatment from monotherapy to combination therapy for complete cancer treatment. Multifunctional bismuth (Bi)‐based nanomaterials (NMs) with therapeutic functions hold great promise for the fields of cancer diagnosis and therapy based on their low toxicity, X‐ray sensitive capabilities, high atomic number, near‐infrared driven semiconductor properties, and low cost. Herein, a comprehensive review of recent advances in various medicinal aspects of Bi‐based NMs is presented including: evaluation of in‐tumor site accumulation, tumor targeting, and therapeutic performance, as well as the characteristics, benefits, and shortcomings of Bi‐based NM‐mediated major monotherapies. In addition, the cooperative enhancement mechanisms between two or more of these monotherapies are described in detail to address common challenges in cancer therapy, such as multidrug resistance, hypoxia, and metastasis. Finally, this review opens new insights into the design of multimodal synergistic therapies for potential future clinical applications of Bi‐based NMs.
Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.
By integrating high-performance CT imaging and photothermal therapy (PTT) into one nanoprobe, an effective theranostic can be achieved for clinical cancer treatment. In this study, the graphene quantum dots (GQDs)-coated bismuth (Bi) nanoparticle (NP) as a theranostic nanoprobe is synthesized and its capabilities for computed tomography (CT) imaging and PTT are investigated. Such nanotheranostic exhibits good physiological dispersity with satisfactory blood compatibility and cytotoxicity. Most importantly, the GQDs-Bi NPs offer strong and steady absorbance profile in NIR region with excellent photostability, which can remarkably convert photo-to-thermal with the photothermal efficiency of 30.0%. Thanks to the powerful PTT effect, co-delivery of GQDs-Bi NPs/NIR laser can effectively induce HeLa cells death in vitro. Cooperatively, NPs hold X-ray attenuation coefficient for high-contrast CT imaging with the corresponding CT improvement efficacy as high as 32.7[Formula: see text]HU[Formula: see text]mg[Formula: see text]. The obtained results highlight the potential of GQDs-Bi NPs as a successful theranostic nanoagent for CT imaging and cancer photothermal therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.